John McHutchison, outgoing Assembly Biosciences CEO
December 19, 2022 11:19 AM ESTUpdated 03:24 PM
R&D

Emerg­ing from he­pati­tis B flops, As­sem­bly Bio show­cas­es ear­ly da­ta on next-gen drugs

Amber Tong

John McHutchi­son will be leav­ing As­sem­bly Bio­sciences with a glimpse at the fu­ture he promised af­ter the biotech ran in­to mul­ti­ple set­backs in its pur­suit …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

Ex­clu­sive: Flag­ship names two CEO-part­ners to lead Va­lo Health, Apri­ori Bio

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times